Through comparing the levels of EIF2S1 S51 phosphorylation in pre‐paclitaxel treatment breast cancer tissues to post‐paclitaxel treatment tissues by immunochemistry analysis, we found a significant increase of phosphorylated EIF2S1 in breast cancer samples following paclitaxel‐based neoadjuvant chemotherapy (Figure 7D‐E). The gene discussed is EIF2S1; the disease is breast carcinoma.